Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report.

Kota ShimokiharaTakashi KawaharaTaisei SuzukiTaku MochizukiDaiji TakamotoJun-Ichi TeranishiYasuhide MiyoshiYasushi YumuraMasahiro YaoHiroji Uemura

Published in: Clinical case reports (2018)

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration-resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Keyphrases

multiple myeloma
rare case
prostate cancer
newly diagnosed
stem cell transplantation
radical prostatectomy
water soluble